Neuregulin (NRG) expression modulates clinical response to trastuzumab in patients with metastatic breast cancer (MBC).

被引：0
|
作者：
De Alava, E.
Abad, M.
Rodriguez, C. A.
Montero, J. C.
Serrano, E.
Ocana, A.
Torres, A.
Ruiz, M.
Cruz, J. J.
Pandiella, A.
机构：
[1] Univ Salamanca, E-37008 Salamanca, Spain
[2] Hosp Univ Salamanca, Salamanca, Spain
[3] Vall Hebron Univ Hosp, Barcelona, Spain
[4] Hosp Univ Rio Hortega, Valladolid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10069
引用
收藏
页码：557S / 557S
页数：1
相关论文
共 50 条
  • [1] Neuregulin (NRG) expression modulates clinical response to herceptin in patients with metastatic breast cancer (MBC)
    de Alava, E.
    Abad, M.
    Ocana, A.
    Rodriguez, C. A.
    Montero, J. C.
    Cruz, J. J.
    Pandiella, A.
    MODERN PATHOLOGY, 2007, 20 : 28A - 28A
  • [2] Neuregulin (NRG) expression modulates clinical response to herceptin in patients with metastatic breast cancer (MBC)
    de Alava, E.
    Abad, M.
    Ocana, A.
    Rodriguez, C. A.
    Montero, J. C.
    Cruz, J. J.
    Pandiella, A.
    LABORATORY INVESTIGATION, 2007, 87 : 28A - 28A
  • [3] Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer
    de Alava, Enrique
    Ocana, Alberto
    Abad, Mar
    Carlos Montero, Juan
    Esparis-Ogando, Azucena
    Rodriguez, Cesar A.
    Otero, Ana P.
    Hernandez, Teresa
    Cruz, Juan J.
    Pandiella, Atanasio
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) : 2656 - 2663
  • [4] Methallotionein expression and outcome in patients with metastatic breast cancer (MBC)
    Rios-Perez, Jorge Arturo
    Abedin, Sameem
    Rosenzweig, Margaret Quinn
    Jung, Su Yon
    Bhargava, Rohit
    Brufsky, Adam
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Trastuzumab use and CNS metastasis in Medicare patients diagnosed with metastatic breast cancer (MBC)
    Griffiths, R.
    Lalla, D.
    Brammer, M.
    Herbert, R.
    Doan, J.
    Danese, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Response of metastatic breast cancer to trastuzumab?
    Barnes, DM
    Miles, DW
    LANCET, 2000, 355 (9199): : 160 - 161
  • [7] DOES OBESITY HAMPER RESPONSE TO TRASTUZUMAB (T) IN POST-MENOPAUSAL PATIENTS (PTS) WITH METASTATIC BREAST CANCER (MBC)?
    Nunez, I.
    Rodriguez-Freixinos, V.
    Sanchez-Olle, G.
    Bellet, M.
    Perez-Garcia, J. M.
    Cortes, J.
    Saura, C.
    Gomez, P.
    Vidal, M.
    Di Cosimo, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 112 - 112
  • [8] Impact of CNS metastases on treatment and survival in patients receiving trastuzumab for metastatic breast cancer (MBC)
    Griffiths, R.
    Lindquist, K.
    Lalla, D.
    Doan, J. F.
    Brammer, M. G.
    Danese, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Predictors of survival in patients with HER2+metastatic breast cancer (MBC) treated with trastuzumab
    Olson, E. M.
    Najita, J. S.
    Sohl, J.
    Arnaout, A.
    Winer, E. P.
    Lin, N. U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Clinical use of trastuzumab (Hereeptin®) in metastatic breast cancer (MBC) in Germany from 2001 to 2006.
    Dackisch, C.
    Eustermann, H.
    Schoenegg, W.
    Soelling, U.
    Stanch, M.
    Goehler, T.
    Kuehn, W.
    Krieger, G.
    Reichert, D.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S186 - S186
12345